リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「A Study of The Effects of Small Molecules on Dicer-mediated Cleavage of Precursor miRNAs (pre-miRNAs)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

A Study of The Effects of Small Molecules on Dicer-mediated Cleavage of Precursor miRNAs (pre-miRNAs)

Sidiq, Nurrohman Muhammad 大阪大学 DOI:10.18910/87832

2022.03.24

概要

MicroRNA (miRNA) is a small (18-22 nucleotides) and evolutionary conserved non- coding RNA that is expressed as a post-transcriptional regulator of living cells and is known to be implicated in various cellular processes and diseases. On the normal condition, miRNA was tightly regulated in the cells, however, the aberrant expression of this type of non-coding RNA would result in cancer, and this type of miRNA is commonly referred to as oncomirs. Inhibition is preferred to overcome this unfavorable overexpression.

A combination screening strategy was used to find a small molecule with the potential to be an inhibitor of miRNA production. This type of screening strategy was a hybrid of target- based screening and cell-based screening. The goal of this combination was to overcome the limitations of target-based screening, which did not take into account the physiological aspects of the living organism, and also cell-based screening, that considered as mechanism- agnostic screening. The combination of both types of screening would increase the relevance of screening results to physiological conditions and make it easier to track the mechanism of action behind the inhibition.

Uterine corpus endometrial carcinoma (UCEC) was chosen to apply those screening concepts due to the lack of alternative drugs available to cure this kind of cancer. Several UCEC-associated miRNAs reported by Favier A., et al. then were used to demonstrate the inhibition of small molecules to the production of UCEC-associated miRNAs (miR-182, miR-31, miR-30d). Nakatani group, on the other hand, developed small molecules with nucleobase recognition sites, such as guanine recognition by N-Acyl-2-amino-7-methyl-1,8-naphthyridine, adenine recognition by 7-methyl-2-oxo-1,8-naphthyridine (azaquinolone), and cytosine recognition by protonated 2-amino-7-methyl-1,8-naphthyridine. These small molecules are designed to specifically bind the complementary nucleobase on the nucleic acids. If those small molecules can bind to miRNA precursors, they may inhibit oncogenic miRNA production. The first chapter of this dissertation described the framework and background of the research. In chapter 2, the use of Real-time PCR (qPCR) to determine the kinetical properties of an in-vitro Dicer reaction was investigated. However, due to a number of challenges, the results of this experiment did not meet the expected results.

In chapter 3, We demonstrated a multistep qPCR-based screening of an in-house chemical library that targets UCEC-associated miRNA production using the screening strategy that combined the target-based screening and cell-based screening assay. In-vitro Dicer-mediated processing of pre-miR-182, pre-miR-31, and pre-miR-30d was used for the initial screening. The first screening yielded 48 different compounds with significant inhibition effects on miRNA production. The inhibitory effect of the identified compounds on the biogenesis of the miRNA targets on the cells was then investigated. We discovered eight hit compounds with potential inhibitory effects on pre-miR-182 and pre-miR-31 processing in vitro and in cells. Furthermore, the interaction of eight compounds with pre-miRNAs was studied using the Surface Plasmon Resonance (SPR) assay and gel analysis. Among eight hit compounds, only 2 compounds showed favorable binding to pre-miRNAs. This suggested two possible ways of inhibition may occur, first, the compounds bind to the pre-miRNA and interfere with the Dicer-mediated cleavage processing, or the compounds directly interact with Dicer and affected the cleavage processing.

参考文献

1. Bartel DP., 2018, Metazoan MicroRNAs. Cell . 173. 20-51

2. Bertel DP., 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215-233

3. O'Brien J, Hayder H, Zayed Y, Peng C., 2018, Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol. 3, 9, 402.

4. Misiewicz-Krzeminska I, Krzeminski P, Corchete LA, et al. 2019, Factors Regulating microRNA Expression and Function in Multiple Myeloma. Noncoding RNA, 5, 1, 9

5. Chen Q, Zhang H, Zhang J, Shen L, Yang J, Wang Y, Ma J, Zhuan B, 2021, miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3. Onco Targets Ther. 14, 3687-3700

6. Itani MM, Nassar FJ, Tfayli AH, Talhouk RS, Chamandi GK, Itani ARS, Makoukji J, Boustany RN, Hou L, Zgheib NK, Nasr RR , 2021, A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer, Int J Mol Sci, 22, 11

7. Xu H, Ding Y, Yang X, 2021, Overexpression of Long Noncoding RNA H19 Downregulates miR-140-5p and Activates PI3K/AKT Signaling Pathway to Promote Invasion, Migration and Epithelial-Mesenchymal Transition of Ovarian Cancer Cells. Biomed Res Int. 2021, 6619730.

8. Zhong S, Golpon H, Zardo P, Borlak J , 2021, miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res. , 230, 164-196.

9. Dias N, Stein CA, 2002, Antisense oligonucleotides: basic concepts and mechanism.Mol Cancer Ther.,1,5, 347-355

10. Krutzfeldt J, Rajewsky N, Braich R, et al., 2005, Silencing of microRNA In vivo with Antagomirs, Nature, 438, 7068, 685-689

11. Petersen M, Nielsen CB, Nielsen KE, Jensen GA, Bondensgaard K, Singh SK, Rajwanshi VK, Koshkin AA, Dahl BM, Wengel J, Jacobsen JP., 2000, The conformations of locked nucleic acids (LNA). J Mol Recognit. 13(1):44-53.

12. Wengel J, Vester B, Lundberg LB, Douthwaite S, Sørensen MD, Babu BR, Gait MJ, Arzumanov A, Petersen M, Nielsen JT. , 2003, LNA and alpha-L-LNA: towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids. 22(5-8):601-4.

13. Zhao Y, Dai Z, Liang Y, Yin M, Ma K, He M, Ouyang H, Teng CB. 2014, Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system. Sci Rep., 3;4:3943.

14. Xiao A, Wang Z, Hu Y, Wu Y, Luo Z, Yang Z, Zu Y, Li W, Huang P, Tong X, Zhu Z, Lin S, Zhang B., 2013, Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res. 41(14):e141.

15. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S. , 1994, Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev. ,4(3):201-6.

16. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO J. 2011 Mar 2;30(5):823-34.

17. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J., . 2015, CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet, 52(5):289-96.

18. Nathan P. Coussens, John C. Braisted, Tyler Peryea, G. Sitta Sittampalam, Anton Simeonov , and Matthew D. Hall, 2017, Small-Molecule Screens: A Gateway to Cancer Therapeutics, Pharmacological Reviews,1, 69 (4) 479-496;

19. Acker MG and Auld DS, 2014, Considerations for the design and reporting of enzyme assays in high throughput screening applications, Perspect Sci, 1, 56-73

20. Haslam C, Hellicar J, Dunn A, Fuetterer A, Hardy N, Marshall P, Paape R, Pemberton M, Resemannand A, Leveridge M. , 2016, The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Throughput Screening: 1536-Well Format and Beyond. J Biomol Screen. 21(2):176-86.

21. Shoemaker RH., 2006, The NCI60 human tumor cell line anticancer drug screen. Nat Rev Cancer. 6(10):813-23.

22. Susan L. Holbeck, Jerry M. Collins and James H. Doroshow, 2010, Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines, 9, 1451-1460

23. Eder J, Sedrani R, Wiesmann C., 2014, The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov., 13(8):577-87.

24. Zhao Y, Mu X, Du G., 2016, Microtubule-stabilizing agents: New drug discovery and cancer therapy. Pharmacol Ther. , 162:134-43.

25. Moffat JG, Rudolph J, Bailey D., 2014, Phenotypic screening in cancer drug discovery past, present, and future. Nat Rev Drug Discov. 13(8):588-602

26. Sponholtz, T.R., et al.,2017, Cancer Causes Control, 28 (6), 579–588

27. Gang Du , Wenqiang Zhang, Zhen Zhang, et al, 2019, HTLV-1-associated genes as potential biomarkers for endometrial cancer, 18, 1, 699-705

28. Siegel, R.L., Miller, K.D., and Jemal A., 2017. C.A. Cancer J. Clin. , 67(1), 7–30.

29. Shaily Arora, Sanjeev Balasubramaniam, Wei Zhang, Lijun Zhang, Rajeshwari Sridhara, Dianne Spillman, Jaigi P. Mathai, Bradley Scott, Sarah J. Golding, Michael Coory, Richard Pazdur and Julia A. Beaver, 2020, FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis, Clin Cancer Res, 26, 19, 5062-5067

30. Favier A, Rocher G, Larsen AK, Delangle R, Uzan C, Sabbah M, Castela M, Duval A, Mehats C, Canlorbe G., 2021, MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review. Cancers (Basel)., 13, 5, 1137.

31. Gunson RN, Collins TC, Carman WF. Practical experience of high throughput real-time PCR in the routine diagnostic virology setting. J Clin Virol. 2006;35(4):355-367.

32. Kramer MF., 2011, Stem-loop RT-qPCR for miRNAs. Curr Protoc Mol Biol, 10-15.10

33. Nakatani, K. 2009, Recognition of Mismatched base pairs in DNA. Bull. Chem. Soc. Jpn, 82, 1055-1069

34. K. Nakatani, S. Sando, I. Saito, 2001, Nat. Biotechnol., 19, 51.

35. K. Nakatani, S. Sando, H. Kumasawa, J. Kikuchi, I. Saito, 2001, J. Am. Chem. Soc., 123, 12650.

36. K. Nakatani, S. Sando, I. Saito, 2001, Bioorg. Med. Chem., 9, 2381.

37. S. Hagihara, H. Kumasawa, Y. Goto, G. Hayashi, A. Kobori, I. Saito, K. Nakatani, 2004, Nucleic Acids Res., 32, 278

38. A. Kobori, S. Horie, H. Suda, I. Saito, K. Nakatani, 2004, J. Am. Chem. Soc. 126, 557.

39. H. Suda, A. Kobori, J. Zhang, G. Hayashi, K. Nakatani, 2005, N,Nʹ-Bis(3-aminopropyl)- 2,7-diamino-1,8-naphthyridine stabilized a single pyrimidine bulge in duplex DNA, Bioorg. Med. Chem 13, 14, 4507-4512

40. A. Murata, T. Otabe, J. Zhang, K. Nakatani, 2016, BzDANP, a Small-Molecule Modulator of pre-miR-29a Maturation by Dicer, ACS Chem Biol, 11, 10, 2790-2796

41. Otabe T, Nagano K, Kawai G, Murata A, Nakatani K., 2019, Inhibition of pre-miRNA- 136 processing by Dicer with small molecule BzDANP suggested the formation of ternary complex of pre-miR-136-BzDANP-Dicer. Bioorg Med Chem. 15, 27, 10, 2140-2148.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る